Gatta, G. et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur. J. Cancer 47, 2493–2511 (2011).
Google Scholar
Prat, J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynaecol. Obstet. 124, 1–5 (2014). This staging classification enables prognostic and management decisions to be inferred.
Google Scholar
Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24, 751–765 (2013).
Google Scholar
Nik, N. N., Vang, R., Shih Ie, M. & Kurman, R. J. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma. Annu. Rev. Pathol. 9, 27–45 (2014).
Google Scholar
Berek, J. S., Renz, M., Kehoe, S., Kumar, L. & Friedlander, M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int. J. Gynaecol. Obstet. 155, 61–85 (2021).
Google Scholar
Gaillard, S. et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J. Clin. Oncol. 43, 868–891 (2025). These guidelines describe the incorporation of neoadjuvant therapy, which has improved potential surgical debulking, known to impact patient survival.
Google Scholar
Pfisterer, J. et al. Optimal treatment duration of bevacizumab as front-line therapy for advanced ovarian cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT OV-15 open-label randomized phase III trial. J. Clin. Oncol. 41, 893–902 (2023).
Google Scholar
Tew, W. P., Lacchetti, C. & Kohn, E. C. Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J. Clin. Oncol. 40, 3878–3881 (2022). These guidelines describe how PARP inhibitor therapy should be used, with the potential of impacting treatment and outcomes for up to half of women with ovarian cancer, improving survival, and even resulting in cure in some.
Google Scholar
Frenel, J. S. et al. Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial. Ann. Oncol. 33, 1021–1028 (2022).
Google Scholar
Markman, M. et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 9, 389–393 (1991).
Google Scholar
Kezlarian, B. et al. Cytologic features of upper gynecologic tract adenocarcinomas exhibiting mesonephric-like differentiation. Cancer Cytopathol. 127, 521–528 (2019).
Google Scholar
Wens, F. et al. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT): patient characteristics, treatment, and outcome — a systematic review. Cancers 15, 3794 (2023).
Google Scholar
Cooke, S. L. et al. The driver mutational landscape of ovarian squamous cell carcinomas arising in mature cystic teratoma. Clin. Cancer Res. 23, 7633–7640 (2017).
Google Scholar
Young, R. H. Ovarian sex cord-stromal tumours and their mimics. Pathology 50, 5–15 (2018).
Google Scholar
Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229–263 (2024). These global cancer statistics allow comparison of ovarian cancer impact and outcomes compared with other cancer types.
Google Scholar
Li, Y. et al. Global, regional, and national burden of breast, cervical, uterine, and ovarian cancer and their risk factors among women from 1990 to 2021, and projections to 2050: findings from the Global Burden of Disease Study 2021. BMC Cancer 25, 330 (2025).
Google Scholar
Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17–48 (2023).
Google Scholar
Garzon, S. et al. Secondary and tertiary ovarian cancer recurrence: what is the best management? Gland. Surg. 9, 1118–1129 (2020).
Google Scholar
Bajwa, A. et al. Challenges and opportunities in ovarian cancer care: a qualitative study of clinician perspectives from 24 low- and middle-income countries. J. Cancer Policy 44, 100582 (2025).
Google Scholar
Chornokur, G., Amankwah, E. K., Schildkraut, J. M. & Phelan, C. M. Global ovarian cancer health disparities. Gynecol. Oncol. 129, 258–264 (2013).
Google Scholar
Funston, G. et al. Experiences of women with ovarian cancer in 22 low-income and middle-income countries (Every Woman Study LMICs): a cross-sectional study. Lancet Obstet. Gynaecol. Womens Health 1, e302–e313 (2025).
Google Scholar
Ren, Y., Xu, R., Wang, Y., Su, L. & Su, J. Global, regional, and national burden of ovarian cancer in women aged 45+ from 1990 to 2021 and projections for 2050: a systematic analysis based on the 2021 Global Burden of Disease Study. J. Cancer Res. Clin. Oncol. 151, 225 (2025).
Google Scholar
Hutchinson, B. et al. Socioeconomic burden of ovarian cancer in 11 countries. JCO Glob. Oncol. 11, e2400313 (2025).
Google Scholar
Silverwood, S. M. et al. Assessing the rates of false-positive ovarian cancer screenings and surgical interventions associated with screening tools: a systematic review. BMJ Oncol. 3, e000404 (2024).
Google Scholar
American Cancer Society. Cancer Facts & Figures 2020 (American Cancer Society, 2020).
Coburn, S. B., Bray, F., Sherman, M. E. & Trabert, B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int. J. Cancer 140, 2451–2460 (2017).
Google Scholar
Wei, Y. F. et al. Worldwide patterns and trends in ovarian cancer incidence by histological subtype: a population-based analysis from 1988 to 2017. EClinicalMedicine 79, 102983 (2025).
Google Scholar
Kroeger, P. T. Jr. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol. 29, 26–34 (2017).
Google Scholar
Peres, L. C. et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. J. Natl Cancer Inst. 111, 60–68 (2019).
Google Scholar
Perren, T. J. Mucinous epithelial ovarian carcinoma. Ann. Oncol. 27, i53–i57 (2016).
Google Scholar
Gonzalez-Martin, A. et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 34, 833–848 (2023).
Google Scholar
Konstantinopoulos, P. A. & Matulonis, U. A. Clinical and translational advances in ovarian cancer therapy. Nat. Cancer 4, 1239–1257 (2023).
Google Scholar
Veneziani, A. C. et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat. Rev. Clin. Oncol. 20, 820–842 (2023). This review provides a broad description of the treatment landscape of different types of ovarian cancer.
Google Scholar
Iida, Y., Okamoto, A., Hollis, R. L., Gourley, C. & Herrington, C. S. Clear cell carcinoma of the ovary: a clinical and molecular perspective. Int. J. Gynecol. Cancer 31, 605–616 (2021).
Google Scholar
Zhu, C. et al. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study. BMC Cancer 21, 322 (2021).
Google Scholar
Ackroyd, S. A. et al. Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma. Gynecol. Oncol. 169, 164–171 (2023).
Google Scholar
Whelan, E. et al. Risk factors for ovarian cancer: an umbrella review of the literature. Cancers 14, 2708 (2022).
Google Scholar
Madakkatel, I. et al. Large-scale analysis to identify risk factors for ovarian cancer. Int. J. Gynecol. Cancer https://doi.org/10.1136/ijgc-2024-005424 (2025).
Google Scholar
Kotsopoulos, J. et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol. Oncol. 150, 85–91 (2018).
Google Scholar
Ivy, S. P., de Bono, J. & Kohn, E. C. The ‘pushmi-pullyu’ of DNA repair: clinical synthetic lethality. Trends Cancer 2, 646–656 (2016). This description of the context in which DNA repair inhibition is likely to be successful in ovarian cancer underpins the current clinical trials and research required to solve the next major challenge — PARP inhibitor resistance.
Google Scholar
Pennington, K. P. et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin. Cancer Res. 20, 764–775 (2014). This description of DNA repair gene mutations and impact on treatment outcomes predicted the following decade of clinical trial outcomes.
Google Scholar
Konstantinopoulos, P. A. et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. J. Clin. Oncol. 38, 1222–1245 (2020). These guidelines provide an approach to best practice of germline and somatic tumour testing of ovarian cancer.
Google Scholar
Kuchenbaecker, K. B. et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 317, 2402–2416 (2017).
Google Scholar
Helder-Woolderink, J. M. et al. Ovarian cancer in Lynch syndrome; a systematic review. Eur. J. Cancer 55, 65–73 (2016).
Google Scholar
Hodan, R. et al. Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer. Cancer Med. 10, 1012–1017 (2021).
Google Scholar
Scaranti, M. et al. Prevalence and clinical implications of mismatch repair (MMR) deficiency in unselected non-serous epithelial ovarian cancer (EOC) patients (pts) [abstract]. J. Clin. Oncol. 37, 1521 (2019).
Google Scholar
Wentzensen, N. et al. Ovarian cancer risk factors by histologic subtype: an analysis from the Ovarian Cancer Cohort Consortium. J. Clin. Oncol. 34, 2888–2898 (2016).
Google Scholar
Ahmed, A. A. et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J. Pathol. 221, 49–56 (2010). The importance of p53, the guardian of the genome, in very early development of nearly all ovarian cancers paves the way for future potential therapeutic approaches.
Google Scholar
Kim, J. et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc. Natl Acad. Sci. USA 109, 3921–3926 (2012).
Google Scholar
Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015).
Google Scholar
Ngoi, N. Y. L. & Tan, D. S. P. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it? ESMO Open. 6, 100144 (2021).
Google Scholar
Ghezelayagh, T. S. et al. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Gynecol. Oncol. 160, 786–792 (2021).
Google Scholar
Ledermann, J. A., Drew, Y. & Kristeleit, R. S. Homologous recombination deficiency and ovarian cancer. Eur. J. Cancer 60, 49–58 (2016).
Google Scholar
Veneziani, A. C., Scott, C., Wakefield, M. J., Tinker, A. V. & Lheureux, S. Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer. Ther. Adv. Med. Oncol. 15, 17588359231157644 (2023).
Google Scholar
Nakayama, N. et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer 116, 2621–2634 (2010).
Google Scholar
Ngoi, N. Y., Sundararajan, V. & Tan, D. S. Exploiting replicative stress in gynecological cancers as a therapeutic strategy. Int. J. Gynecol. Cancer 30, 1224–1238 (2020).
Google Scholar
Patch, A. M. et al. Whole-genome characterization of chemoresistant ovarian cancer. Nature 521, 489–494 (2015).
Google Scholar
Wiegand, K. C. et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 363, 1532–1543 (2010).
Google Scholar
Sun, M. & Jiang, W. Ovarian clear cell carcinoma with or without endometriosis origin in a single institution cohort. Discov. Oncol. 14, 39 (2023).
Google Scholar
Gadducci, A. et al. Clear cell carcinoma of the ovary: epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol. Oncol. 162, 741–750 (2021).
Google Scholar
Bogani, G. et al. Clear cell carcinoma of the endometrium. Gynecol. Oncol. 164, 658–666 (2022).
Google Scholar
Sun, Y. & Liu, G. Endometriosis-associated ovarian clear cell carcinoma: a special entity? J. Cancer 12, 6773–6786 (2021).
Google Scholar
Beddows, I. et al. Cell state of origin impacts development of distinct endometriosis-related ovarian carcinoma histotypes. Cancer Res. 84, 26–38 (2024).
Google Scholar
Collins, K. E. et al. Transcriptomic analyses of ovarian clear-cell carcinoma with concurrent endometriosis. Front. Endocrinol. 14, 1162786 (2023).
Google Scholar
Bolton, K. L. et al. Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin. Cancer Res. 28, 4947–4956 (2022).
Google Scholar
Chen, S. et al. A review of the clinical characteristics and novel molecular subtypes of endometrioid ovarian cancer. Front. Oncol. 11, 668151 (2021).
Google Scholar
Hollis, R. L. et al. Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome. Nat. Commun. 11, 4995 (2020).
Google Scholar
Zwimpfer, T. A. et al. Low grade serous ovarian cancer — a rare disease with increasing therapeutic options. Cancer Treat. Rev. 112, 102497 (2023).
Google Scholar
Cobb, L. & Gershenson, D. Novel therapeutics in low-grade serous ovarian cancer. Int. J. Gynecol. Cancer 33, 377–384 (2023).
Google Scholar
Grisham, R. N. et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119, 548–554 (2013).
Google Scholar
Manning-Geist, B. et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin. Cancer Res. 28, 4456–4465 (2022).
Google Scholar
Babaier, A. & Ghatage, P. Mucinous cancer of the ovary: overview and current status. Diagnostics 10, 52 (2020).
Google Scholar
Morice, P., Gouy, S. & Leary, A. Mucinous ovarian carcinoma. N. Engl. J. Med. 380, 1256–1266 (2019).
Google Scholar
Cheasley, D. et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat. Commun. 10, 3935 (2019).
Google Scholar
Gorringe, K. L. et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol. Oncol. 156, 552–560 (2020).
Google Scholar
Nugawela, D. & Gorringe, K. L. Targeted therapy for mucinous ovarian carcinoma: evidence from clinical trials. Int. J. Gynecol. Cancer 33, 102–108 (2023).
Google Scholar
Ho, G. Y. et al. Epithelial-to-mesenchymal transition supports ovarian carcinosarcoma tumorigenesis and confers sensitivity to microtubule targeting with eribulin. Cancer Res. 82, 4457–4473 (2022).
Google Scholar
Barker, H. E. & Scott, C. L. Genomics of gynaecological carcinosarcomas and future treatment options. Semin. Cancer Biol. 61, 110–120 (2020).
Google Scholar
Ramphal, K., Hadfield, M. J., Bandera, C. M., Hart, J. & Dizon, D. S. Genomic and molecular characteristics of ovarian carcinosarcoma. Am. J. Clin. Oncol. 46, 572–576 (2023).
Google Scholar
Narod, S. A. et al. Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers. J. Natl Cancer Inst. 116, 1753–1760 (2024).
Google Scholar
Steenbeek, M. P. et al. Risk of peritoneal carcinomatosis after risk-reducing salpingo-oophorectomy: a systematic review and individual patient data meta-analysis. J. Clin. Oncol. 40, 1879–1891 (2022).
Google Scholar
Li, Z., Fang, X. & Wang, S. Omentum provides a special cell microenvironment for ovarian cancer. Cancer Rep. 6, e1858 (2023).
Burger, R. A. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol. Oncol. 121, 230–238 (2011).
Google Scholar
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Google Scholar
Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203–213 (2003). This description of the impact of immune cells on ovarian cancer treatment outcomes suggests that addressing this major challenge is crucial.
Google Scholar
Blanc-Durand, F., Clemence Wei Xian, L. & Tan, D. S. P. Targeting the immune microenvironment for ovarian cancer therapy. Front. Immunol. 14, 1328651 (2023).
Google Scholar
Goff, B. A. et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 109, 221–227 (2007).
Google Scholar
Ebell, M. H., Culp, M. B. & Radke, T. J. A systematic review of symptoms for the diagnosis of ovarian cancer. Am. J. Prev. Med. 50, 384–394 (2016).
Google Scholar
Sevinc, A., Adli, M., Kalender, M. E. & Camci, C. Benign causes of increased serum CA-125 concentration. Lancet Oncol. 8, 1054–1055 (2007).
Google Scholar
Vanderpuye, V. D. et al. Assessment of adult women with ovarian masses and treatment of epithelial ovarian cancer: ASCO resource-stratified guideline. JCO Glob. Oncol. 7, 1032–1066 (2021). These guidelines describe the diagnostic approach to women with an ovarian mass and appropriate approaches to treatment.
Google Scholar
Franciszek Dluski, D., Mierzynski, R., Poniedzialek-Czajkowska, E. & Leszczynska-Gorzelak, B. Ovarian cancer and pregnancy — a current problem in perinatal medicine: a comprehensive review. Cancers 2, 3795 (2020).
Google Scholar
Fruscio, R. et al. Epithelial ovarian cancer and borderline tumors during pregnancy: a report from the International Network on Cancer, Infertility, and Pregnancy. Int. J. Gynecol. Cancer 35, 100053 (2025).
Google Scholar
Miyamoto, T., Murphy, B. & Zhang, N. Intraperitoneal metastasis of ovarian cancer: new insights on resident macrophages in the peritoneal cavity. Front. Immunol. 14, 1104694 (2023).
Google Scholar
Guffanti, F., Mengoli, I. & Damia, G. Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches. Front. Oncol. 14, 1405361 (2024).
Google Scholar
Ledermann, J. A. et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann. Oncol. 35, 248–266 (2024). This consensus conference report details the pathology and molecular biology of ovarian cancer.
Google Scholar
Banerjee, S. N. et al. Efficacy and safety of avutometinib ± defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60/GOG-3052/RAMP 201. J. Clin. Oncol. 43, 2782–2792 (2025).
Google Scholar
Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436–2445 (2023).
Google Scholar
Dilawari, A. et al. FDA approval summary: mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant ovarian cancer. Clin. Cancer Res. 29, 3835–3840 (2023).
Google Scholar
Menon, U. et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 397, 2182–2193 (2021). This large trial shows that screening for ovarian cancer is not yet effective as it is does not improve survival.
Google Scholar
Gohagan, J. K. et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control. Clin. Trials 21, 251S–272S (2000).
Google Scholar
Buys, S. S. et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA 305, 2295–2303 (2011).
Google Scholar
Kobayashi, H. et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int. J. Gynecol. Cancer 18, 414–420 (2008).
Google Scholar
Sideris, M., Menon, U. & Manchanda, R. Screening and prevention of ovarian cancer. Med. J. Aust. 220, 264–274 (2024).
Google Scholar
Finch, A. P. et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J. Clin. Oncol. 32, 1547–1553 (2014).
Google Scholar
Parker, W. H. et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study. Obstet. Gynecol. 121, 709–716 (2013).
Google Scholar
Lee, Y. J. et al. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers. J. Gynecol. Oncol. 28, e3 (2017).
Google Scholar
Samimi, G., Trabert, B., Geczik, A. M., Duggan, M. A. & Sherman, M. E. Population frequency of serous tubal intraepithelial carcinoma (STIC) in clinical practice using SEE-Fim protocol. JNCI Cancer Spectr. 2, pky061 (2018).
Google Scholar
Medeiros, F. et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30, 230–236 (2006).
Google Scholar
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04294927 (2025).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT04251052 (2026).
Hanley, G. E. et al. Outcomes from opportunistic salpingectomy for ovarian cancer prevention. JAMA Netw. Open. 5, e2147343 (2022).
Google Scholar
Daly, M. B. et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 19, 77–102 (2021).
Google Scholar
National Comprehensive Cancer Network. NCCN Guidelines: Breast, Ovarian, and Pancreatic Cancer Genetic Assessment. Version 1.2025 (National Comprehensive Cancer Network, 2025).
Colombo, N. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann. Oncol. 30, 672–705 (2019).
Google Scholar
European Society of Gynaecological Oncology. Ovarian Cancer Pocket Guidelines: based on ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer (European Society of Gynaecological Oncology, 2025).
Sessa, C. et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Ann. Oncol. 34, 33–47 (2023).
Google Scholar
Vergote, I. et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 19, 1680–1687 (2018).
Google Scholar
Harter, P. et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N. Engl. J. Med. 380, 822–832 (2019).
Google Scholar
Morice, P. et al. Fertility-sparing treatment and follow-up in patients with cervical cancer, ovarian cancer, and borderline ovarian tumours: guidelines from ESGO, ESHRE, and ESGE. Lancet Oncol. 25, e602–e610 (2024).
Google Scholar
Straubhar, A., Chi, D. S. & Long Roche, K. Update on the role of surgery in the management of advanced epithelial ovarian cancer. Clin. Adv. Hematol. Oncol. 18, 723–731 (2020).
Google Scholar
Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L. & Montz, F. J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20, 1248–1259 (2002).
Google Scholar
Chang, S. J., Hodeib, M., Chang, J. & Bristow, R. E. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol. Oncol. 130, 493–498 (2013).
Google Scholar
Colombo, N. & Ledermann, J. A. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Ann. Oncol. 32, 1300–1303 (2021). These guidelines provide treatment recommendations for newly diagnosed ovarian cancer.
Google Scholar
Fotopoulou, C. et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int. J. Gynecol. Cancer 30, 436–440 (2020).
Google Scholar
Aronson, S. L. et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial. Lancet Oncol. 24, 1109–1118 (2023).
Google Scholar
Ceelen, W., Demuytere, J. & de Hingh, I. Hyperthermic intraperitoneal chemotherapy: a critical review. Cancers 13, 3114 (2021).
Google Scholar
Armstrong, D. K. et al. Ovarian cancer, version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc Netw. 19, 191–226 (2021).
Google Scholar
Tewari, K. S. et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J. Clin. Oncol. 37, 2317–2328 (2019).
Google Scholar
Oza, A. M. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 16, 928–936 (2015).
Google Scholar
Vergote, I. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N. Engl. J. Med. 363, 943–953 (2010).
Google Scholar
Gourley, C., Walker, J. L. & Mackay, H. J. Update on intraperitoneal chemotherapy for the treatment of epithelial ovarian cancer. Am. Soc. Clin. Oncol. Educ. Book. 35, 143–151 (2016).
Google Scholar
Walker, J. L. et al. Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology/Gynecologic Oncology Group study. J. Clin. Oncol. 37, 1380–1390 (2019).
Google Scholar
Wright, A. A. et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J. Clin. Oncol. 33, 2841–2847 (2015).
Google Scholar
Nagao, S. et al. Intraperitoneal carboplatin for ovarian cancer — a phase 2/3 trial. NEJM Evid. 2, EVIDoa2200225 (2023).
Google Scholar
Clamp, A. R. et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. Lancet 394, 2084–2095 (2019).
Google Scholar
Banerjee, S. et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1721–1731 (2021).
Google Scholar
DiSilvestro, P. et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J. Clin. Oncol. 41, 609–617 (2023).
Google Scholar
Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Ann. Oncol. 34, 681–692 (2023).
Google Scholar
Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416–2428 (2019).
Google Scholar
Gonzalez-Martin, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391–2402 (2019).
Google Scholar
Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial. Ann. Oncol. 35, 981–992 (2024).
Google Scholar
Monk, B. J. et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). J. Clin. Oncol. 40, 3952–3964 (2022).
Google Scholar
Kondrashova, O. et al. Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 7, 984–998 (2017).
Google Scholar
Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (parts 1 and 2). Nat. Commun. 12, 2487 (2021).
Google Scholar
Monk, B. J. et al. ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC) [abstract LBA30]. Ann. Oncol. 35, S1223–S1224 (2024).
Google Scholar
Pignata, S. et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J. Clin. Oncol. 29, 3628–3635 (2011).
Google Scholar
Wagner, U. et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br. J. Cancer 107, 588–591 (2012).
Google Scholar
Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039–2045 (2012).
Google Scholar
Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302–1308 (2014).
Google Scholar
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F. & Hamilton, T. C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res. 57, 850–856 (1997).
Google Scholar
Harter, P. et al. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N. Engl. J. Med. 385, 2123–2131 (2021).
Google Scholar
Jiang, R. et al. Surgery versus no surgery in platinum-sensitive relapsed ovarian cancer: final overall survival analysis of the SOC-1 randomized phase 3 trial. Nat. Med. 30, 2181–2188 (2024).
Google Scholar
Coleman, R. L. et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N. Engl. J. Med. 381, 1929–1939 (2019).
Google Scholar
Harter, P. et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann. Surg. Oncol. 13, 1702–1710 (2006). This trial demonstrated when surgery is an advantage in recurrent ovarian cancer.
Google Scholar
Tian, W. J. et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann. Surg. Oncol. 19, 597–604 (2012).
Google Scholar
Pfisterer, J. et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol. 21, 699–709 (2020).
Google Scholar
Parmar, M. K. et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361, 2099–2106 (2003).
Google Scholar
Coleman, R. L. et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 18, 779–791 (2017).
Google Scholar
Pujade-Lauraine, E. et al. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial. Ann. Oncol. 34, 1152–1164 (2023).
Google Scholar
Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 620–631 (2021).
Google Scholar
Lorusso, D. et al. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. Int. J. Gynecol. Cancer 34, 550–558 (2024).
Google Scholar
Baert, T. et al. The systemic treatment of recurrent ovarian cancer revisited. Ann. Oncol. 32, 710–725 (2021).
Google Scholar
Poveda, A. M. et al. Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial. J. Clin. Oncol. 33, 3836–3838 (2015).
Google Scholar
Dy, G. K., Farooq, A. V. & Kang, J. J. Ocular adverse events associated with antibody-drug conjugates for cancer: evidence and management strategies. Oncologist 29, e1435–e1451 (2024).
Google Scholar
Grisham, R. N. et al. Molecular results and potential biomarkers identified from the phase 3 MILO/ENGOT-ov11 study of binimetinib versus physician choice of chemotherapy in recurrent low-grade serous ovarian cancer. Clin. Cancer Res. 29, 4068–4075 (2023).
Google Scholar
Monk, B. J. et al. MILO/ENGOT-ov11: binimetinib versus physician’s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. J. Clin. Oncol. 38, 3753–3762 (2020).
Google Scholar
US Food and Drug Administration. FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian cancer. FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low (2025).
US National Library of Medicine. ClinicalTrials.gov https://www.clinicaltrials.gov/study/NCT06072781 (2026).
Gore, M. et al. An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol. Oncol. 153, 541–548 (2019).
Google Scholar
Campbell, R. et al. Patient-reported outcomes in ovarian cancer: facilitating and enhancing the reporting of symptoms, adverse events, and subjective benefit of treatment in clinical trials and clinical practice. Patient Relat. Outcome Meas. 14, 111–126 (2023).
Google Scholar
Kurtz, J. E. et al. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: a position paper from the GCIG symptom benefit committee. Gynecol. Oncol. 161, 502–507 (2021).
Google Scholar
Gnanasakthy, A., Russo, J., Gnanasakthy, K., Harris, N. & Castro, C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp. Clin. Trials 120, 106860 (2022).
Google Scholar
Kargo, A. S., Coulter, A., Jensen, P. T. & Steffensen, K. D. Proactive use of PROMs in ovarian cancer survivors: a systematic review. J. Ovarian Res. 12, 63 (2019).
Google Scholar
Aiyegbusi, O. L., Nair, D., Peipert, J. D., Schick-Makaroff, K. & Mucsi, I. A narrative review of current evidence supporting the implementation of electronic patient-reported outcome measures in the management of chronic diseases. Ther. Adv. Chronic Dis. 12, 20406223211015958 (2021).
Google Scholar
Denis, F. et al. Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer. JAMA 321, 306–307 (2019).
Google Scholar
Pearce, F. J. et al. The role of patient-reported outcome measures in trials of artificial intelligence health technologies: a systematic evaluation of ClinicalTrials.gov records (1997–2022). Lancet Digit. Health 5, e160–e167 (2023).
Google Scholar
Power, J., Brown, L. & Ritvo, P. A qualitative study examining psychosocial distress, coping, and social support across the stages and phases of epithelial ovarian cancer. Health Care Women Int. 29, 366–383 (2008).
Google Scholar
Schulman-Green, D., Ercolano, E., Dowd, M., Schwartz, P. & McCorkle, R. Quality of life among women after surgery for ovarian cancer. Palliat. Support. Care 6, 239–247 (2008).
Google Scholar
Goff, B. Symptoms associated with ovarian cancer. Clin. Obstet. Gynecol. 55, 36–42 (2012).
Google Scholar
Rickard, B. P. et al. Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response. Cancers 13, 4318 (2021).
Google Scholar
Dunton, C. J. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 7, 11–19 (2002).
Google Scholar
Pergialiotis, V. et al. Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature. Support. Care Cancer 30, 7147–7157 (2022).
Google Scholar
Beesley, V. L. et al. When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecol. Oncol. 159, 179–186 (2020).
Google Scholar
Temel, J. S. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N. Engl. J. Med. 363, 733–742 (2010).
Google Scholar
Harter, P. et al. Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial. Ann. Oncol. 36, 185–196 (2025).
Google Scholar
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089–2108 (2024).
Google Scholar
Richardson, D. L., Eskander, R. N. & O’Malley, D. M. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 9, 851–859 (2023).
Google Scholar
Katsumata, N. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 14, 1020–1026 (2013).
Google Scholar
Clamp, A. et al. ICON8B: GCIG phase III randomised trial comparing weekly dose-dense chemotherapy + bevacizumab to three-weekly chemotherapy + bevacizumab in first-line high-risk stage III-IV epithelial ovarian cancer treatment: primary progression-free survival analysis [abstract #159]. Int. J. Gynecol. Cancer 33, A424 (2023).
Chan, J. K., Brady, M. F. & Monk, B. J. Weekly vs. every-3-week paclitaxel for ovarian cancer. N. Engl. J. Med. 374, 2603–2604 (2016).
Google Scholar
Vasey, P. A. et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J. Natl Cancer Inst. 96, 1682–1691 (2004).
Google Scholar
Pignata, S. et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 15, 396–405 (2014).
Google Scholar
Armstrong, D. K. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34–43 (2006).
Google Scholar
Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495–2505 (2018).
Google Scholar
Li, N. et al. Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial. JAMA Oncol. 9, 1230–1237 (2023).
Google Scholar
Pujade-Lauraine, E. et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J. Clin. Oncol. 28, 3323–3329 (2010).
Google Scholar
Aghajanian, C. et al. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol. Oncol. 139, 10–16 (2015).
Google Scholar
Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).
Google Scholar
Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017).
Google Scholar
Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949–1961 (2017).
Google Scholar
Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).
Google Scholar
Mutch, D. G. et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 25, 2811–2818 (2007).
Google Scholar
Moore, K. N. et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N. Engl. J. Med. 389, 2162–2174 (2023).
Google Scholar
Sisodia, R. C. & del Carmen, M. G. Lesions of the ovary and fallopian tube. N. Engl. J. Med. 387, 727–736 (2022).
Google Scholar
